Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Drug Saf

Retrieve available abstracts of 26 articles:
HTML format



Single Articles


    December 2022
  1. WAN EYF, Chui CSL, Mok AHY, Xu W, et al
    mRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination and Risk of Adverse Events and Acute Diabetic Complications in Patients with Type 2 Diabetes Mellitus: A Population-Based Study.
    Drug Saf. 2022;45:1477-1490.
    PubMed     Abstract available


    October 2022
  2. KAUR U, K L A, Chauhan M, Joshi A, et al
    A Prospective Observational Study on BBV152 Coronavirus Vaccine Use in Adolescents and Comparison with Adults: Interim Results of the First Real-World Safety Analysis.
    Drug Saf. 2022;45:1099-1109.
    PubMed     Abstract available


    September 2022
  3. LANE S, Shakir S
    Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.
    Drug Saf. 2022;45:1003-1008.
    PubMed     Abstract available


    August 2022
  4. KANT A, van Hunsel F
    Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:925-926.
    PubMed    


  5. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".
    Drug Saf. 2022;45:923.
    PubMed    


    July 2022
  6. HARPAZ R, DuMouchel W, Van Manen R, Nip A, et al
    Signaling COVID-19 Vaccine Adverse Events.
    Drug Saf. 2022;45:765-780.
    PubMed     Abstract available


    June 2022
  7. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
    Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
    Drug Saf. 2022;45:685-698.
    PubMed     Abstract available


    May 2022
  8. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
    Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Drug Saf. 2022;45:535-548.
    PubMed     Abstract available


    April 2022
  9. KANT A, Jansen J, van Balveren L, van Hunsel F, et al
    Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Drug Saf. 2022;45:319-331.
    PubMed     Abstract available


    February 2022
  10. FERNER RE, Stevens RJ, Anton C, Aronson JK, et al
    Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
    Drug Saf. 2022;45:137-144.
    PubMed     Abstract available


    December 2021
  11. LUXI N, Giovanazzi A, Capuano A, Crisafulli S, et al
    COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
    Drug Saf. 2021;44:1247-1269.
    PubMed     Abstract available


    November 2021
  12. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
    Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
    Drug Saf. 2021;44:1125-1149.
    PubMed     Abstract available


  13. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
    Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Drug Saf. 2021;44:1209-1214.
    PubMed     Abstract available


    October 2021
  14. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
    Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
    PubMed     Abstract available


    September 2021
  15. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    PubMed     Abstract available


  16. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    PubMed     Abstract available


    June 2021
  17. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    PubMed     Abstract available


    April 2021
  18. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed    


  19. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    PubMed     Abstract available


    February 2021
  20. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    PubMed    


    January 2021
  21. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    PubMed     Abstract available


  22. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    PubMed    


    December 2020
  23. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    PubMed     Abstract available


  24. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available


  25. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available


  26. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: